Vol. 6 No. 2 (2026)
Reimbursement Recommendations

Risperidone In Situ Microparticle Long-Acting Injection (Okedi)

decorative image of the issue cover

Published February 9, 2026

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Okedi should be reimbursed by public drug plans for the treatment of schizophrenia if certain conditions are met.
  • Okedi should only be covered by public drug plans for the treatment of adult patients with schizophrenia.
  • Reimbursement for Okedi should be based on the criteria used by each of the public drug plans for the initiation and renewal of other long-acting injection (LAI) atypical antipsychotic drugs for the treatment of adults with schizophrenia, and the cost of Okedi should not exceed that of the least costly LAI atypical antipsychotic reimbursed for the treatment of schizophrenia.